Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACHV Stock Price Chart Interactive Chart >
ACHV Price/Volume Stats
| Current price | $8.24 | 52-week high | $16.10 |
| Prev. close | $8.17 | 52-week low | $6.55 |
| Day low | $8.06 | Volume | 8,645 |
| Day high | $8.35 | Avg. volume | 45,157 |
| 50-day MA | $7.70 | Dividend yield | N/A |
| 200-day MA | $8.35 | Market Cap | 77.89M |
Achieve Life Sciences, Inc. (ACHV) Company Bio
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV News From Around the Web
Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual ConferenceSEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows: H.C. Wainwright BIOCONNECT Virtual Conference: Date: January 10, 2022 Time: 7:00 am ET Investors can register for the conference HERE . Following the conference, a webcast replay of the presentation will be available on Full story available on Benzinga.com |
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking CessationTopline ORCA-2 Results Expected in Q2 2022SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021. The ORCA-2 trial is the first |
Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical DevelopmentSEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. ("SVB"). The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness to Achieve at closing on December 22, 2021. Subject to the terms and conditions of the ... |
Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation ProgramAchieve Life Sciences Inc (NASDAQ: ACHV) has entered into a million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. Related: Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation. As part of the contingent convertible debt agreement, SVB will fund $15 million in the fo |
Geode Capital Management LLC Purchases 27,379 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)Geode Capital Management LLC grew its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 93.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,669 shares of the biopharmaceutical companys stock after acquiring an additional 27,379 shares [] |
ACHV Price Returns
| 1-mo | 11.50% |
| 3-mo | 1.35% |
| 6-mo | 5.91% |
| 1-year | -18.09% |
| 3-year | -69.02% |
| 5-year | -99.32% |
| YTD | 5.91% |
| 2021 | -3.95% |
| 2020 | -23.57% |
| 2019 | -56.21% |
| 2018 | -90.97% |
| 2017 | -75.64% |
Loading social stream, please wait...